Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejso.2022.04.010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Safety and Suitability of DNA Sequencing of Tissue Biopsies Performed on Patients Referred to a Phase I Unit.
Cancers (Basel)
December 2024
Division of Early Drug Development, European Institute of Oncology, IRCCS, 20141 Milan, Italy.
Background: Early-phase clinical trials offer a unique opportunity for patients with cancer. These trials often mandate biopsies to collect tumor tissue for research purposes, requiring patients to undergo invasive procedures. Some trials mandate molecular prescreening, but the success of these analyses relies on the quality and quantity of the tested materials.
View Article and Find Full Text PDFDeep learning algorithm on H&E whole slide images to characterize alterations frequency and spatial distribution in breast cancer.
Comput Struct Biotechnol J
December 2024
Division of Pathology, European Institute of Oncology IRCCS, Milan, Italy.
The tumor suppressor is frequently mutated in hormone receptor-negative, HER2-positive breast cancer (BC), contributing to tumor aggressiveness. Traditional ancillary methods like immunohistochemistry (IHC) to assess functionality face pre- and post-analytical challenges. This proof-of-concept study employed a deep learning (DL) algorithm to predict mutational status from H&E-stained whole slide images (WSIs) of BC tissue.
View Article and Find Full Text PDFReply to Letter to the Editor: 'Large Language Models: Could They Be the Next Generation of Clinical Decision Support Systems in Cardiovascular Diseases?'.
Anatol J Cardiol
July 2024
Department of Cardiology, Health Sciences University, Sultan Abdulhamid Han Training and Research Hospital, İstanbul, Türkiye.
Standardized molecular pathology workflow for ctDNA-based ESR1 testing in HR+/HER2- metastatic breast cancer.
Crit Rev Oncol Hematol
September 2024
Division of Pathology, European Institute of Oncology IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. Electronic address:
Mutations in the estrogen receptor alpha gene (ESR1) can lead to resistance to endocrine therapy (ET) in hormone receptor-positive (HR+)/ HER2- metastatic breast cancer (MBC). ESR1 mutations can be detected in up to 40 % of patients pretreated with ET in circulating tumor DNA (ctDNA). Data from prospective randomized trials highlight those patients with HR+/HER2- MBC with detectable ESR1 mutations experience better outcomes when receiving novel selective estrogen receptor degraders (SERDs).
View Article and Find Full Text PDFExpression of immune-related genes and breast cancer recurrence in women with ductal carcinoma in situ.
Eur J Cancer
May 2024
Division of Cancer Prevention and Genetics, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Background And Aim: Ductal carcinoma in situ (DCIS) is a non-obligate precursor of invasive breast cancer with highly variable clinical behavior, but risk stratification is still challenging. We sought to identify immune-related gene expression signatures of pure DCIS associated with different risks of breast cancer recurrence.
Methods: A retrospective nested case-control study of 143 pure DCIS was performed including 70 women with subsequent ipsilateral breast event (IBE, in situ or invasive; cases) and 73 DCIS women with no IBE and matched for age, tumor size, treatment, hormone receptors/HER2 status, and follow-up time (controls).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!